SOUTH SAN FRANCISCO, Calif., May 30, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the publication of a peer-reviewed paper in Expert Opinion on Pharmacotherapy featuring the Company's lead product candidate, vosaroxin. In addition to an overview of the chemistry, pharmacokinetics and clinical development of vosaroxin, including the ongoing Phase 3 VALOR and Phase 2/3 LI-1 trials, the paper explores the potential advantages of vosaroxin over anthracycline therapy, including overcoming resistance mechanisms, more site-selective DNA damage, and reduced formation of DNA adducts and reactive oxygen species resulting in better tolerability. The paper, entitled "Vosaroxin: a new valuable tool with the potential to replace anthracyclines in the treatment of AML?" is expected to be published in the July 2013 (Volume 14, Number 10) issue of the print publication and is currently available online ( click here to link).
Vosaroxin Review Published In Expert Opinion On Pharmacotherapy
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.